Genentech, Inc.
NEWS
It was another busy week for clinical trial news. Here’s a look.
AC Immune’s Phase II Lauriet study of investigational anti-Tau monoclonal antibody, semorinemab, in mild-to-moderate Alzheimer’s disease (AD), only met one endpoint.
Sungho Han, Ph.D., founder and CEO of Genuv Inc. in Seoul, South Korea, has built her career and her company by thinking outside the box.
Vaccinations will be required by January 4 under the new White House plan.
The FDA reviewed Tecentriq under Project Orbis, allowing the simultaneous submission and review of potential oncology treatments to international regulatory bodies.
It was yet another busy week for clinical trial announcements. Take a look.
The 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis ran from October 13 to 15, with companies globally presenting cutting-edge studies on MS.
BrainStorm announced positive data from a Phase II safety and efficacy study of NurOwn in progressive MS on Thursday morning.
At the virtual Congress of the ECTRIMS meeting this week, multiple companies present data for ongoing studies of therapies for multiple sclerosis. BioSpace takes a look at some of the data.
JOBS
IN THE PRESS